

**EXPERIENCE IN PERSONALIZED CELL THERAPY CLINICAL IMPLEMENTATION FOR TREATMENT OF PATIENTS WITH PRIMARY ENDOTHELIAL DYSTROPHY AFTER PHACOEMULSIFICATION**

© S.Yu. Astakhov¹, I.A. Riks¹, S.S. Papanyan¹, A.A. Kasparov², Evg.A. Kasparova², A.S. Pavlyuk³, K. Fedotova¹

¹Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation, Saint Petersburg, Russia;

²Federal State Budgetary Scientific Institution Research Institute of Eye Diseases, Moscow, Russia;

³Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia

For citation: Astakhov SYu, Riks IA, Papanyan SS, et al. Experience in personalized cell therapy clinical implementation for treatment of patients with primary endothelial dystrophy after phacoemulsification. *Ophthalmology Journal*. 2017;10(4):6-12. doi: 10.17816/OV1046-12

Received: 26.10.2017

Accepted: 27.11.2017

✧ The article presents treatment results of the personalized cell therapy (PCT) method in patients with early post-operative bullous keratopathy which developed in eyes with pre-existing primary Fuchs' corneal endothelial dystrophy (ED). The patented PCT consists in incubating *in vitro* the patient's blood with the stimulator (polyA:polyU), collecting serum with activated leukocytes weighted in it, and introducing the obtained cell preparation in the anterior chamber of the patient's eye. The study included 12 patients with ED and pseudophakia. The observation period ranged from 8 to 12 months. The therapeutic effect of PCT was obtained in 58.3% of cases, allowing to avoid further surgical procedures. To achieve a good therapeutic effect, several PCT sessions are recommended. To date, PCT is the only effective therapeutic treatment method for early corneal edema after phacoemulsification.

✧ **Keywords:** cornea; epithelial and endothelial dystrophy; corneal endothelial cells; Fuchs' endothelial corneal dystrophy; confocal microscopy; cell therapy; bullous keratopathy.

ОПЫТ КЛИНИЧЕСКОГО ПРИМЕНЕНИЯ ПЕРСОНАЛИЗИРОВАННОЙ КЛЕТЧНОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ С ПЕРВИЧНОЙ ЭНДОТЕЛИАЛЬНОЙ ДИСТРОФИЕЙ ПОСЛЕ ФАКОЗМУЛЬСИФИКАЦИИ

© С.Ю. Астахов¹, И.А. Рикс¹, С.С. Папаян¹, А.А. Каспаров², Евг.А. Каспарова², А.С. Павлюк³, К. Федотова¹

¹ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург;

²ФГБНУ НИИ глазных болезней, Москва;

³ФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», Москва

Для цитирования: Астахов С.Ю., Рикс И.А., Папаян С.С., и др. Опыт клинического применения персонализированной клеточной терапии для лечения больных с первичной эндотелиальной дистрофией после факоэмульсификации // Офтальмологические ведомости. — 2017. — Т. 10. — № 4. — С. 6–12. doi: 10.17816/OV1046-12

Поступила в редакцию: 26.10.2017

Принята к печати: 27.11.2017

✧ В статье представлены результаты лечения больных с ранней послеоперационной буллезной кератопатией, развившейся на глазах с преобладающей первичной эндотелиальной дистрофией роговицы (ЭД) Фукса с помощью методики персонализированной клеточной терапии (ПКТ). Запатентованный

метод ПКТ заключается в инкубации *in vitro* крови пациента со стимулятором (полиА : полиУ), сборе сыворотки со взвешенными в ней активированными лейкоцитами и введении полученного клеточного препарата в переднюю камеру глаза пациента. В работу вошли 12 пациентов с ЭД и артифакцией. Срок наблюдения составил от 8 до 12 месяцев. Терапевтический эффект ПКТ был зафиксирован в 58,3 % случаев, что позволило избежать дальнейших хирургических вмешательств. Рекомендуется проведение нескольких сеансов ПКТ для достижения хорошего терапевтического эффекта. ПКТ является единственным эффективным на сегодняшний день методом терапевтического лечения ранних отёков роговицы после факоэмульсификации.

✦ **Ключевые слова:** роговица; эндотелиальная дистрофия (ЭД); эндотелиальные клетки; дистрофия роговицы Фукса; конфокальная микроскопия; клеточная терапия; буллёзная кератопатия.

INTRODUCTION

The treatment of corneal disorders is currently one of the most significant challenges in ophthalmology. According to reports of the World Health Organization, corneal disorders are the third most common cause of blindness [3]. Every fifth patient who seeks ophthalmic care develops degenerative, inflammatory, or traumatic lesions of the cornea [5, 10]. An increasing incidence of Fuchs endothelial corneal dystrophy (FECD), which often develops following intraocular surgeries such as phacoemulsification (PE), has also been observed. These patients usually require surgical treatment with keratoplasty. FECD is one of the most common indications (up to 25% of all indications) for keratoplasty in the United States and Europe [9, 11–14]. This procedure is associated with a high risk of transplant rejection and other complications, and some patients may even require repeated surgery. It has been clarified that pharmacotherapy is often ineffective for corneal dystrophy and does not restore corneal transparency. Therefore, the search for new drugs and methods to stimulate metabolism and proliferation in the corneal endothelium remains relevant.

Since the early 2000s, a group of researchers (A.A. Kasparov, E.A. Kasparova, and A.S. Pavliuk) at the Research Institute of Eye Diseases has been successfully using personalized cell therapy (PCT) for treating early (arising at 1–3 months after surgery) postoperative bullous keratopathy [1, 2, 4–8]. The method is protected by the following two patents: “Method for treating post-inflammatory bullous keratopathy (No 2165747)” and “Novel medication for treating corneal edema and other manifestations of early bullous keratopathy: technology of its production and administration (No 2357743).” This medical tech-

nology was registered in 2013 (protocol No 4 dated 03.06.2013) and approved by the Ethics Committee of the Research Institute of Eye Diseases. The Department of Ophthalmology is authorized to use PCT; the method was also approved by the Ethics Committee of the Pavlov First Saint Petersburg State Medical University (April 2016).

PCT involves the *in vitro* activation of autologous leukocytes from the peripheral blood through successive injections of Poludanum (a complex of polyadenylic acid and polyuridylic acid that acts as an immunomodulator) into the anterior chamber. Poludanum is the only immunomodulatory drug approved for intraocular administration. PCT stimulates the local production of cytokines, including interferon (IFN)- α , IFN- β , IFN- γ , interleukin (IL)-2, IL-6, IL-8, and tumor necrosis factor (TNF)- α . Together with IL-8, proinflammatory cytokines that are released after this stimulation weaken intercellular contact, which probably abrogates the contact inhibition of mitosis, allowing endothelial cells to proliferate and migrate. The antiapoptotic effect is facilitated by growth factors, including transforming growth factor β (TGF- β), platelet-derived growth factor, and vascular endothelial growth factor, produced by activated leukocytes that are injected into the anterior chamber where their concentration is usually low [1]. Moreover, these growth factors facilitate the production of extracellular matrix, thus stabilizing the barrier function of the corneal endothelium. Kasparova et al. demonstrated that the suspension of activated cells used for injections contains a layer of leukocytes between a clot formed by red blood cells and plasma. The average concentration of these leukocytes is $1.341 \pm 0.12 \times 10^6$ cells/mL; of these, 35% are mononuclear cells [2]. The authors of the method also demonstrated that activated cells

continue to release cytokines and growth factors after being injected into the anterior chamber, increasing their *in vivo* concentration [3].

MATERIALS AND METHODS

This study included 12 patients with early postoperative bullous keratopathy, which developed following PE in eyes with pre-existing primary FECD. All patients were examined and treated at the Ophthalmology Clinic of the Pavlov First Saint Petersburg State Medical University. Most of the patients were females ($n = 10$). The patients' age varied between 48 and 83 years (mean age, 69.5 ± 11.6 years). The majority of participants (83.3%) were older than 61 years. All patients were diagnosed with stage 1 or 2 primary FECD (according to the classification of V.V. Volkov and M.M. Dronov, 1978) and pseudophakia. In total, 11 patients developed FECD within 1 or 2 months post cataract surgery (PE) and intraocular lens implantation; 1 patient developed FECD at 5 months post-surgery.

All patients were routinely admitted to the clinic after general examination. Ophthalmologic examination included visual acuity testing; slit-lamp indirect ophthalmoscopy (Nidek, Japan) with photo- and video-recording of pathological changes in the conjunctiva and cornea; and the biomicroscopy of the conjunctiva, cornea, and anterior segment of the eyeball. All patients also underwent confocal microscopy examination using the Confoscan-4 confocal microscope (Nidek, Japan), ocular ultrasound examination (ultrasonic A- and B-scanning, ocular biometry), ultrasonic pachymetry, optical pachymetry using the Tomey optical biometer, and tonometry using the Icare tonometer or pneumotometry. Patients with stage 1 FECD (bullous keratopathy) showed *cornea guttata*; pathological changes were detected only in the endothelial layer of the cornea, and the estimated central corneal thickness (CCT) was 540–550 μm . Confocal microscopy revealed reduced corneal endothelial cell density (ECD), moderate polymegathism, and areas of endothelial cell loss. Patients with stage 1 FECD complained of blurred vision (primarily in the morning); none of them experienced pain.

Patients with stage 2 FECD showed persistent stromal edema detected by biomicroscopy and confocal microscopy. In three patients, ECD could not

be estimated because of stromal edema. In more than 70% of the corneal area, there were Descemet's membrane (DM) folds, and CCT exceeded 590 μm . All patients showed significantly reduced visual acuity, none of them experienced pain.

Because the majority of patients presented with corneal edema, refractometry could not be performed. Mean visual acuity was 0.1 (maximum, 0.1; minimum, 0.01). None of the patients has been previously diagnosed with any disorders of the ocular fundus. However, the condition of the cornea did not allow its examination during the study.

Prior to PCT, ECD could be measured only in four patients. Mean preoperative ECD was 1269 cells/ mm^2 (minimum, 912 cells/ mm^2), and mean CCT was 664 μm (maximum, 804 μm ; minimum, 551 μm). Intraocular pressure (IOP) was within the normal limits in all patients.

PCT was performed in an operating room. After epibulbar anesthesia, serum with activated leukocytes was slowly injected into the anterior chamber through paracentesis. Five patients received two injections at an interval of 7–10 days, and seven patients received only one injection. After PCT, all patients were followed-up for 8–12 months.

RESULTS AND DISCUSSION

In the early postoperative period (few hours after PCT), two patients experienced ocular pain and had increased IOP (up to 23 mm Hg), which was treated with IOP-lowering eye drops. The remaining patients reported no complaints except for a sprained feeling in the operated eye that lasted for several hours after PCT.

At 3 months post-PCT, mean CCT decreased to 598.4 μm (maximum, 750 μm). Complete resolution of corneal folds and restoration of corneal transparency were observed in seven patients. Mean visual acuity increased to 0.27, reaching 0.4, 0.5, and 0.7 in three patients (these patients received two injections).

Unfortunately, not all patients received the second injection, primarily because they missed their visits to the clinic. No recurrence of corneal edema was observed in any patient.

The patients' characteristic and the duration of follow-up are summarized in Table 1. Seven patients showed positive dynamics, including corneal edema resorption and a reduction in or even

Clinical data before and after personalized cell therapy

Table 1

Таблица 1

Клинические данные до процедуры персонализированной клеточной терапии и после неё

Case number	Visual acuity		Central corneal thickness (μm)		Endothelial cell density (cells/ mm^2)		Time of follow-up
	before PCT	after PCT	before PCT	after PCT	before PCT	after PCT	
1	0.15	0.1	622	688	n/d*	n/d*	8
2	0.1	0.4	705	716	1548	1627	8
3	0.1	0.01	727	543**	1392	1640	9
4	0.2	0.05	551**	739	912	900	12
5	0.05	0.3	765**	760	1227	2300	12
6	0.1	0.02	784	550**	n/d	1667	12
7	0.01	0.7	552**	560	n/d	1612	10
8	0.15	0.5	560	600	n/d	1500	10
9	0.25	0.2	570	760	n/d	n/d	9
10	0.05	0.3	551**	580	n/d	1200	9
11	0.1	0.3	780	540	n/d	1350	10
12	0.1	0.4	804	600	n/d	1100	10


Note: *n/d, cannot be reliably determined due to the state of the cornea; **Central corneal thickness was not determined reliably; there was considerable variation in the pachymetry results; values indicate means

a resolution of Descemet's membrane folds. CCT decreased in all patients. Confocal microscopy revealed no pathological changes in the epithelium and stroma following PCT, except for moderate polymegethism and slightly decreased pleomorphism. The positive effects were first registered at 10–14 days following PCT and remained stable during the follow-up period. Images of the eyes of patients who exhibited a good therapeutic effect following PCT are presented (Figures 1–3).

Among the patients who exhibited no therapeutic effect, five participants showed the same or decreased visual acuity following PCT. In most of these patients, CCT did not change and remained $>600 \mu\text{m}$. In some cases, CCT at pachymetry could not be reliably determined due to significant changes in the epithelium (bullae and stromal edema). All these patients had received only one injection of activated cells, and they exhibited no positive dynamics during the follow-up period.



a



b

Fig. 1. Patient G.: *a* — before personalized cell therapy — pronounced stromal edema, coarse DM folds, density of endothelial cells is not reliably determined. Visual acuity is 0.1; *b* — 7 days after personalized cell therapy: reduction of stromal edema, restoration of corneal transparency, and decrease in the number of DM folds (smoothing out $\approx 70\%$ of DM folds). Visual acuity — 0.3

Рис. 1. Пациентка Г.: *a* — до персонализированной клеточной терапии — выраженный отёк стромы, грубые складки десцеметовой оболочки (ДО), плотность эндотелиальных клеток достоверно не определяется. Острота зрения — 0,1; *b* — через 7 дней после персонализированной клеточной терапии: уменьшение отёка стромы, восстановление прозрачности роговицы и уменьшение количества складок ДО (расправление $\approx 70\%$ складок ДО). Острота зрения — 0,3




Fig. 2. Patient N.: *a* — before personalized cell therapy: pronounced diffuse stromal edema in the center of the cornea, single bullae, gentle DM folds, endothelial cell density is not reliably determined. Visual acuity is 0.1; *b* — 7 days after personalized cell therapy: resorption of stromal edema in the optical center, but in the paracentral zone there is an area of a local stromal edema preserved, corneal transparency is restored, there are no folds. Visual acuity — 0.4; *c* — endothelial microscopy. The density of endothelial cells after 7 days is 1729 cells/mm², polymegatism — 62.8%, pleomorphism — 28.5%

Рис. 2. Пациент Н.: *a* — до персонализированной клеточной терапии: выраженный диффузный отёк стромы в центре роговицы, единичные буллы, нежные складки ДО, плотность эндотелиальных клеток достоверно не определяется. Острота зрения — 0,1; *b* — через 7 дней после персонализированной клеточной терапии: резорбция отёка стромы в оптическом центре, но в парацентральной зоне сохраняется участок локального отёка стромы, восстановление прозрачности роговицы, складок ДО нет. Острота зрения — 0,4; *c* — эндотелиальная микроскопия. Плотность эндотелиальных клеток через 7 дней — 1729 кл/мм², полимегатизм — 62,8 %, плеоморфизм — 28,5 %




Fig. 3. Patient M.: *a* — before personalized cell therapy: moderately pronounced edema of the endothelium. The density of endothelial cells is not reliably determined, visual acuity is 0.01; *b* — 14 days after personalized cell therapy: decrease of the edema of the endothelium, restoration of corneal transparency, no DM folds. Visual acuity is 0.4, endothelial cell density is 1600 cells/mm²; *c* — 4 months after the 2nd session of personalized cell therapy: persistent mild edema of the endothelium, visual acuity — 0.7, density of endothelial cells — 1612 cells/mm²

Рис. 3. Пациентка М.: *a* — до персонализированной клеточной терапии: умеренно выраженный отёк эндотелия. Плотность эндотелиальных клеток достоверно не определяется, острота зрения — 0,01; *b* — через 14 дней после персонализированной клеточной терапии: уменьшение отёка эндотелия, восстановление прозрачности роговицы, складок ДО нет. Острота зрения — 0,4, плотность эндотелиальных клеток — 1600 кл/мм²; *c* — через 4 месяца после 2-го сеанса персонализированной клеточной терапии: сохраняется лёгкий отёк эндотелия, острота зрения — 0,7, плотность эндотелиальных клеток — 1612 кл/мм²

Confocal microscopy at 8–10 months post-PCT revealed edema in all corneal layers, thickening of Bowman's membrane, pronounced tortuosity of nerve fibers, fibrosis in the superficial layers of the corneal stroma, hyperreflexivity of the corneal stroma, and irregular orientation of collagen fibrils in the stroma. In some cases, the endothelium could not be reliably visualized; in the remaining cases, pronounced polymegathism (70%) and reduced hexagonality of endothelial

cells (to 25%–30%) were observed. Ultimately, these patients underwent keratoplasty ($n = 4$) or descemetorhexis ($n = 1$).

CONCLUSION

1. PCT is a highly effective method for treating stages 1 and 2 bullous keratopathies that develop following PE in eyes with pre-existing FECD.
2. A good therapeutic effect of PCT was observed in 58.3% of the patients, and the need for ad-

ditional surgical interventions, such as keratoplasty, was eliminated.

3. PCT is currently the only effective method for treating early corneal edema following PE.
4. To achieve a good therapeutic effect, performing several injections of activated cells is recommended.
5. PCT is a well-reproducible method, and this aspect is important for its implementation into routine clinical practice once all the permissions required by the Russian Federation have been obtained.

The authors declare no conflict of interest or competing financial interest.

REFERENCES

1. Аветисов С.Э., Суббот А.М., Антохин А.И., и др. Персонализированная клеточная терапия в офтальмологии (II): цитокиновый профиль аутогенного клеточного продукта // *Гены и клетки*. – 2012. – Т. 7. – № 1. – С. 49–53. [Avetisov SJe, Subbot AM, Antohin AI, et al. Personalizirovannaja kletocchnaja terapija v oftal'mologii (II): citokinovyy profil' avtogenno go kletocchno go produkta. *Geny i kletki*. 2012;7(1):49-53. (In Russ.)]
2. Аветисов С.Э., Суббот А.М., Антохин А.И., и др. Персонализированная клеточная терапия в офтальмологии. I. Метод получения и цитотип аутологичного клеточного продукта. *Клеточная трансплантология и тканевая инженерия*. 2011. – Т. 6. – № 2. – С. 38–42. [Avetisov SJe, Subbot AM, Antohin AI, et al. Personalizirovannaja kletocchnaja terapija v oftal'mologii. I. Metod poluchenija i citofenotip autologichno go kletocchno go produkta. *Kletocchnaja transplantologija i tkanevaja inzhenerija*. 2011;6(2):38-42. (In Russ.)]
3. Информационный бюллетень ВОЗ [Электронный ресурс]. – 2009, май, № 282. [Informatsionnyy byulleten' VOZ [Elektronnyy resurs]. – 2009, may, № 282. (In Russ.)]. <http://whodc.mednet.ru/bulletin>.
4. Каспаров А.А., Каспарова Евг.А., Фадеева Л.Л., и др. Персонализированная клеточная терапия ранней буллезной кератопатии (экспериментальное обоснование и клинические результаты) // *Вестник офтальмологии*. – 2013. – Т. 129. – № 5. – С. 52–61. [Kasparov AA, Kasparova EvgA, Fadeeva LL, et al. Personalizirovannaja kletocchnaja terapija rannej bulleznoj keratopatii (jeksperimental'noe obosnovanie i klinicheskie rezul'taty). *Vestnik oftal'mologii*. 2013;129(5):52-61. (In Russ.)]
5. Каспаров А.А., Каспарова Евг.А., Павлюк А.С. Локальная экспресс-аутоцитокотерапия (комплекс цитокинов) в лечении вирусных и невирусных поражений глаз // *Вестник офтальмологии*. – 2004. – Т. 120. – № 1. – С. 29–32. [Kasparov AA, Kasparova EvgA, Pavljuk AS. Lokal'naja jekspress-autocitokoterapija (kompleks citokinov) v lechenii virusnyh i nevirusnyh porazhenij glaz. *Vestnik oftal'mologii*. 2004;120(1):29-32. (In Russ.)]
6. Каспарова Е.А. Локальная экспресс-аутоцитокотерапия в лечении заболеваний переднего отдела глаза: Дис. ... канд. мед. наук. – М., 2001. [Kasparova EA. Lokal'naja jekspress-autocitokoterapija v lechenii zabolevanij perednego otdela glaza [dissertation]. Moscow, 2001. (In Russ.)]
7. Каспарова Евг.А., Бородина Н.В., Суббот А.М. Прижизненная конфокальная микроскопия для оценки эффективности персонализированной клеточной терапии при лечении ранней послеоперационной буллезной кератопатии // *Вестник офтальмологии*. – 2012. – Т. 128. – № 1. – С. 26–33. [Kasparova EvgA, Borodina NV, Subbot AM. Prizhiznennaja konfokal'naja mikroskopija dlja ocenki jeffektivnosti personalizirovannoj kletocchnoj terapii pri lechenii rannej posleoperacionnoj bulleznoj keratopatii. *Vestnik oftal'mologii*. 2012;128(1):26-33. (In Russ.)]
8. Каспарова Евг.А., Суббот А.М., Калинина Д.Б. Проллиферативный потенциал заднего эпителия роговицы человека // *Вестник офтальмологии*. – 2013. – Т. 129. – № 3. – С. 82–88. [Kasparova EvgA, Subbot AM, Kalinina DB. Proliferativnyj potencial zadnego jepitelija rogovicy cheloveka. *Vestnik oftal'mologii*. 2013;129(3):82-88. (In Russ.)]
9. Каспарова Евг.А., Суббот А.М., Антохин А.И., и др. Клиническая эффективность персонализированной клеточной терапии заболеваний эндотелия роговицы // *Катарактальная и рефракционная хирургия*. – 2011. – Т. 11. – № 2. – С. 45–49. [Kasparova EvgA, Subbot AM, Antohin AI, et al. Klinicheskaja jeffektivnost' personalizirovannoj kletocchnoj terapii zabolevanij jendotelija rogovicy. *Kataraktal'naja i refrakc. hir.* 2011;11(2):45-49. (In Russ.)]
10. Мороз З.И., Тахчиди Х.П., Калинин Ю.Ю. и др. Современные аспекты кератопластики // *Федоровские чтения: Сб. науч. тр.* – М., 2004. – С. 280–288 [Moroz ZI, Takhchidi KhP, Kalinnikov YuYu, et al. Sovremennye aspekty keratoplastiki. *Fedorovskie chteniya: Sb. nauch. Tr.* Moscow, 2004. P. 280-288. (In Russ.)].
11. Al-Yousuf N, Mavrikakis E, et al. Penetrating keratoplasty: indications over a 10 year period. *Br J Ophthalmol*. 2004;88(8):998-1001.
12. Brady SE, Rapuano CJ, Arentsen JJ, et al. Clinical indications for and procedures associated with penetrating keratoplasty, 1983-1988. *Am J Ophthalmol*. 1989;108(2):118-122. doi: 10.1016/0002-9394(89)90003-2.
13. Cursiefen C, Kuchle M, Naumann GO. Changing indications for penetrating keratoplasty: histopathology 1250 of corneal buttons. *Cornea*. 1998;17(5):468-470. doi: 10.1097/00003226-199809000-00002.
14. Dobbins KR, Price FW, Whitson WE. Trends in the indications for penetrating keratoplasty in the Midwestern United State. *Cornea*. 2000;19(6):813-816. doi: 10.1097/00003226-200011000-00010.

15. Kang PC, Klintworth GK, Kim T, et al. Trends in the indications for penetrating keratoplasty, 1980-2001. *Cornea*. 2005;24(7):801-803. doi: 10.1097/01.icc.0000157407.43699.22.
16. Lois N, Kowal VO, Cohen EJ. Indications for penetrating keratoplasty and associated procedures 1989-1995. *Cornea*. 1997;16(6):623-629. doi: 10.1097/00003226-199711000-00004.

Information about the authors

Sergey Yu. Astakhov — MD, PhD, DMedSc, professor, head of the department. Ophthalmology Department. Academician I.P. Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russia (St. Petersburg, Russia). E-mail: astakhov73@mail.ru.

Inna A. Riks — MD, PhD, assistant. Ophthalmology department. Academician I.P. Pavlov First St. Petersburg State Medical University, Saint Petersburg, Russia. E-mail: riks0503@yandex.ru.

Sanasar S. Papanyan — MD, aspirant. Ophthalmology department. Academician I.P. Pavlov First St. Petersburg State Medical University, Saint Petersburg, Russia. E-mail: dr.papanyan@yandex.ru.

Arkadiy A. Kasparov — DMedSc, professor, head of corneal pathology department. Research Institute of Eye Diseases, Moscow, Russia. E-mail: kasparov17@mail.ru.

Evgeniya A. Kasparova — PhD, senior research assistant. Corneal pathology department. Research Institute of Eye Diseases, Moscow, Russia. E-mail: kasparova_jane@mail.ru.

Aleksandr S. Pavlyuk — DMedSc, professor. Immunology department. Pirogov Russian National Research Medical University, Moscow, Russia. E-mail: treg4@yandex.ru.

Karolina Fedotova — Aspirant. Ophthalmology department. Academician I.P. Pavlov First St. Petersburg State Medical University, Saint Petersburg, Russia. E-mail: karo-luna@mail.ru.

Сведения об авторах

Сергей Юрьевич Астахов — д-р мед. наук, профессор, заведующий кафедрой офтальмологии с клиникой. ФГБОУ ВО «ПСПбГМУ им. И.П. Павлова» Минздрава России, Санкт-Петербург. E-mail: astakhov73@mail.ru.

Инна Александровна Рикс — канд. мед. наук, ассистент кафедры офтальмологии с клиникой. ФГБОУ ВО «ПСПбГМУ им. И.П. Павлова» Минздрава России, Санкт-Петербург. E-mail: riks0503@yandex.ru.

Санасар Сурикович Папаян — аспирант кафедры офтальмологии с клиникой. ФГБОУ ВО «ПСПбГМУ им. И.П. Павлова» Минздрава России, Санкт-Петербург. E-mail: dr.papanyan@yandex.ru.

Аркадий Александрович Каспаров — д-р мед. наук, профессор, заведующий отделом патологии роговицы. ФГБНУ НИИ глазных болезней, Москва. E-mail: kasparov17@mail.ru.

Евгения Аркадьевна Каспарова — канд. мед. наук, старший научный сотрудник отдела патологии роговицы. ФГБНУ НИИ глазных болезней, Москва. E-mail: kasparova_jane@mail.ru.

Александр Сергеевич Павлюк — д-р мед. наук, профессор, кафедры иммунологии ФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», Москва. E-mail: treg4@yandex.ru.

Каролина Федотова — аспирант кафедры офтальмологии с клиникой ФГБОУ ВО «ПСПбГМУ им. И.П. Павлова» Минздрава России, Санкт-Петербург. E-mail: karo-luna@mail.ru.